Skip Navigation

Innovations

  • In the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI), our mission is to facilitate the transfer of research innovations from the laboratory to the clinic through timely commercialization, and to help Dana-Farber investigators create these innovations through collaborations and relationships with industry.

    As a bridge between research and industry, BODFI is committed to building relationships with companies both large and small, with the investor community, and with entrepreneurs. Our goal is to create solutions.

  • At BODFI, we will:

  • Technology News

    Study of Rare Ovarian Cancer Sheds Light on Epigenetic Cancer Process

    Using a rare, lethal form of ovarian cancer as a lens, scientists at Dana-Farber Cancer Institute have discovered how the loss of two key, enzymatic parts of a gene-regulating protein complex in cells can drive them into malignant growth.

    Investigators led by Cigall Kadoch, PhD, found that when two components that serve as the “engines” of the SWI/SNF chromatin remodeling complex are both mutated – as they invariably are in the rare ovarian cancer type known as SCCOHT– genes that are normally expressed in the healthy ovary are shut off, and genes that allow the cell cycle to run unchecked are turned on.

    Unusual Mechanism of CDK4/6 Inhibitor Resistance Found, May Be Reversible

    Breast cancer cells can acquire resistance to the relatively new drugs known as CDK4/6 inhibitors by producing higher amounts of CDK6, a cell cycle protein, a new study has found, and those cells can transfer their resistant traits to other cancer cells via molecular carriers called exosomes.

    This drug resistance mechanism, identified by researchers at Dana-Farber Cancer Institute, is highly unusual, they said, and laboratory studies suggest it may be reversible. Breast cancer cells that developed resistance to a CDK4/6 inhibitor, palbociclib, became sensitive to the drug again after a “treatment holiday” of several weeks when no palbociclib was administered, they said in an article in Cell Reports.